RxDoctor Payments DataLook up a doctor →

Erica Dailey, DO

Gastroenterology · Overland Park, KSNPI 1760893184

Payments from drug & device makers

$32,912in general payments, 2019–2025

Across 699 payments — averaging $47.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Scientific Affairs, LLC$10K
  • AbbVie$5K
  • Madrigal Pharmaceuticals$4K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • Johnson & Johnson$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • plus $8K from 39 others

What the payments were for

  • Consulting fees$8,54026%
  • Speaking & faculty fees$3,99612%
  • Grants$8303%
  • Travel & lodging$1,5585%
  • Food & beverage$17,78254%
  • Education$2061%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,912 in reported general payments places this provider in the 80th percentile of 98 gastroenterology providers in Kansas.

See all gastroenterology providers in Kansas

Medicare billing

Part B allowed, 2024
$99,121
Medicare patients
427
Services billed
869

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi On-BodyRisankizumab-Rzaa17$337,325
StelaraUstekinumab13$333,384
CreonLipase/Protease/Amylase26$197,227
XifaxanRifaximin18$74,043
LinzessLinaclotide46$49,299
ViberziEluxadoline11$16,739
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C34$4,809
Pantoprazole Sodium168$2,815
Omeprazole81$1,982
Dicyclomine Hcl16$582
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl26$356
Ondansetron Hcl13$297
Mirtazapine12$282
Spironolactone13$275
Amitriptyline Hcl15$178

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$1,911$333,38413 claims
AbbVieCreon, Linzess, Viberzi$4,688$263,26583 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu$1,657$78,85352 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 98 gastroenterology providers in Kansas.

Other gastroenterology in Overland Park

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →